<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">636694</article-id><article-id pub-id-type="doi">10.17816/KMJ636694</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinicopathological features of glomerulopathies and their prognostic significance in cancers of different sites</article-title><trans-title-group xml:lang="ru"><trans-title>Клинико-морфологические особенности гломерулопатий и их прогностическое значение при злокачественных опухолях различной локализации</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-1684-8917</contrib-id><contrib-id contrib-id-type="researcherid">LJM-2852-2024</contrib-id><name-alternatives><name xml:lang="en"><surname>Vinnikov</surname><given-names>Daniel L.</given-names></name><name xml:lang="ru"><surname>Винников</surname><given-names>Даниэль Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>student</p></bio><bio xml:lang="ru"><p>студент</p></bio><email>danvin2004@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-9862-3194</contrib-id><name-alternatives><name xml:lang="en"><surname>Mukhametshina</surname><given-names>Adelya R.</given-names></name><name xml:lang="ru"><surname>Мухаметшина</surname><given-names>Аделя Рамилевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>student</p></bio><bio xml:lang="ru"><p>студент</p></bio><email>Mukhametshina.dely@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-9414-8674</contrib-id><name-alternatives><name xml:lang="en"><surname>Lebedev</surname><given-names>Petr V.</given-names></name><name xml:lang="ru"><surname>Лебедев</surname><given-names>Пётр Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>student</p></bio><bio xml:lang="ru"><p>студент</p></bio><email>petrlebedev_03@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-9236-6714</contrib-id><name-alternatives><name xml:lang="en"><surname>Podverbnaya</surname><given-names>Yulia S.</given-names></name><name xml:lang="ru"><surname>Подвербная</surname><given-names>Юлия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>student</p></bio><bio xml:lang="ru"><p>студент</p></bio><email>julia_123_julia_123@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-3772-6643</contrib-id><contrib-id contrib-id-type="scopus">57189492346</contrib-id><contrib-id contrib-id-type="researcherid">KVY-3412-2024</contrib-id><contrib-id contrib-id-type="spin">2641-6658</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulanov</surname><given-names>Dmitry V.</given-names></name><name xml:lang="ru"><surname>Буланов</surname><given-names>Дмитрий Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), Assist. Prof., Depart. of Pathological Anatomy, Clinical Pathological Anatomy</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доц., каф. патологической анатомии и клинической патологической анатомии</p></bio><email>dbulanov81@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian National Research Medical University named after N.I. Pirogov</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">First Moscow State Medical University named after I.M. Sechenov</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-03-27" publication-format="electronic"><day>27</day><month>03</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-04-20" publication-format="electronic"><day>20</day><month>04</month><year>2025</year></pub-date><volume>106</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>258</fpage><lpage>266</lpage><history><date date-type="received" iso-8601-date="2024-10-03"><day>03</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-12-17"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-04-20"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/636694">https://kazanmedjournal.ru/kazanmedj/article/view/636694</self-uri><abstract xml:lang="en"><p>This review analyzes international studies from the past five years that focus on glomerulopathies associated with malignant neoplasms of different sites. This study aimed to conduct a comparative analysis of histological and immunohistochemical features of morphological characteristics in glomerulopathies in cancer of different localizations, as well as identification of the specificity of the revealed features.<bold> </bold>Relevant publications were identified through <italic>Scopus</italic>, <italic>PubMed</italic>, and the <italic>Cochrane</italic><italic> </italic><italic>Library</italic>, with a search limited to studies published from 2019 to 2024. The review provides a detailed analysis of histological and immunohistochemical alterations in the glomerular apparatus in glomerulopathies associated with carcinomas of different sites. The identified morphological changes were assessed for their specificity. Particular attention is given to pathogenetic mechanisms that may underlie the development of glomerulopathies associated with carcinomas of different sites. A detailed analysis of the available literature demonstrates that understanding the histological and immunohistochemical features of glomerulopathies associated with malignant tumors contributes to improving diagnostic approaches for these conditions. Research in this area is of considerable importance, as it may offer new insights for the development of innovative strategies aimed at advancing prognosis and quality of life in patients with malignancies. Malignant cells are capable of expressing various substances, including proteins, that may contribute to the pathogenesis of glomerulopathies. Morphological evaluation of the glomerular apparatus enables the identification or exclusion of a pathogenetic association between the tumor and glomerulopathy, thereby allowing adjustment of the patient’s treatment plan. The review also discusses potential pathophysiological mechanisms of tumor-associated glomerulopathies, contributing to more accurate interpretation of glomerular changes and enabling differentiation between specific and paraspecific morphological features. In summary, this review presents an analysis of the histological and immunohistochemical features of glomerulopathies associated with malignant tumors of different sites, highlighting the importance of an interdisciplinary approach to diagnosing this condition as one of the clinical manifestations of malignancy.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре литературы проанализированы результаты зарубежных исследований, которые посвящены гломерулопатиям при злокачественных новообразованиях различной локализации, полученных за последние 5 лет. Целью обзора является проведение сравнительного анализа гистологических и иммуногистохимических особенностей морфологических характеристик гломерулопатий при злокачественных новообразованиях различной локализации, а также определение специфичности выявленных особенностей. Данные исследования найдены с использованием баз данных Scopus, PubMed, Cochrane Library и ограничены датой публикации с 2019 по 2024 г. В работе выполнен детальный анализ гистологических и иммуногистохимических изменений гломерулярного аппарата при гломерулопатиях, ассоциированных с карциномами различной локализации. Выявленные изменения оценены для определения специфичности приведённых морфологических особенностей. Особое внимание уделено патогенетическим механизмам, предположительно объясняющим развитие гломерулопатий при карциномах различной локализации. Подробный анализ данных литературы по приведённой теме доказывает, что понимание гистологических и иммуногистохимических особенностей морфологических характеристик гломерулопатий при злокачественных новообразованиях способствует совершенствованию методов диагностики подобных состояний. Важность исследований в этой области невозможно переоценить, т. к. они могут предоставить новые данные для создания инновационных подходов, направленных на улучшение прогноза и качества жизни пациентов, страдающих онкологическими заболеваниями. Клетки злокачественной опухоли способны экспрессировать различные вещества, в том числе белки, которые могут приводить к развитию гломерулопатии. Анализ морфологических изменений гломерулярного аппарата позволяет выявить наличие или отсутствие патогенетической связи опухоли с гломерулопатией и скорректировать курс лечения больного. Кроме того, часть обзора посвящена разбору возможных патофизиологических механизмов развития гломерулопатий при злокачественных новообразованиях, что способствует более точной диагностике морфологических изменений клубочков, позволяет разграничить между собой специфические и параспецифические морфологические характеристики. Таким образом, обзор литературы представляет собой анализ гистологических и иммуногистохимических особенностей морфологических характеристик гломерулопатий при злокачественных новообразованиях различной локализации, с учётом значимости междисциплинарного подхода в диагностике данного состояния, как одного из клинических проявлений злокачественных опухолей.</p></trans-abstract><kwd-group xml:lang="en"><kwd>glomerulopathies</kwd><kwd>malignant neoplasms</kwd><kwd>membranous nephropathy</kwd><kwd>review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гломерулопатии</kwd><kwd>злокачественные новообразования</kwd><kwd>мембранозная нефропатия</kwd><kwd>обзор</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bonilla M, Gudsoorkar P, Wanchoo R, et al. Onconephrology 2022: An Update. Kidney360. 2023;4(2):258–271. doi: 10.34067/KID.0001582022</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Thet Z, Lam AK, Ranganathan D, et al. Critical evaluation of cancer risks in glomerular disease. Transl Oncol. 2022;19:101376. doi: 10.1016/j.tranon.2022.101376</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zhang X, Khurana A, Hirani S, et al. Paraneoplastic Glomerulonephropathy Associated With Renal Cell Carcinoma: A Descriptive Analysis of Published Reports. Cureus. 2023;15(3):e36928. doi: 10.7759/cureus.36928</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Galloway J. Remarks ON HODGKIN’S DISEASE. Br Med J. 1922;2(3234):1201–1208.2. doi: 10.1136/bmj.2.3234.1201</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Romagnani P, Kitching AR, Leung N, Anders HJ. The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC). Nephrol Dial Transplant. 2023;38(Supplement_2):ii3–ii10. doi: 10.1093/ndt/gfad067</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Yang CK, Lee CY, Wang HS, et al. Glomerular disease classification and lesion identification by machine learning. Biomed J. 2022;45(4):675–685. doi: 10.1016/j.bj.2021.08.011</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lamba P, Nam KH, Contractor J, Kim A. Nephritic Syndrome. Prim Care. 2020;47(4):615–629. doi: 10.1016/j.pop.2020.08.003</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bharati J, Chander PN, Singhal PC. Parietal Epithelial Cell Behavior and Its Modulation by microRNA-193a. Biomolecules. 2023;13(2):266. doi: 10.3390/biom13020266</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Liu S, Wan Y, Hu Z, et al. Nephrotic syndrome associated with solid malignancies: a systematic review. BMC Nephrol. 2024;25(1):215. doi: 10.1186/s12882-024-03632-9</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mizdrak M, Smajic B, Mizdrak I, et al. Endocrine Disorders in Nephrotic Syndrome-A Comprehensive Review. Biomedicines. 2024;12(8):1860. doi: 10.3390/biomedicines12081860</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yu X, Fan Z, Chen W, Wang Z. Lung cancer with nephrotic syndrome as a paraneoplastic syndrome: A case report. Mol Clin Oncol. 2020;13(6):86. doi: 10.3892/mco.2020.2156</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kaira K, Amano H, Imai H, et al. Membranous Nephropathy as a Paraneoplastic Syndrome in Cancer of Unknown Primary. In Vivo. 2024;38(3):1503–1508. doi: 10.21873/invivo.13598</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wang L, Wang J, Xu A, et al. Future embracing: exosomes driving a revolutionary approach to the diagnosis and treatment of idiopathic membranous nephropathy. J Nanobiotechnology. 2024;22(1):472. doi: 10.1186/s12951-024-02633-y</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Garkusha TA, Stolyarevich ES, Khorzhevsky VA, Ivliev SV. Glomerulopathy in kidney neoplasms: frequency of occurrence, structure of morbidity. Russian Journal of Archive of Pathology. 2023;85(2):21–26. doi: 10.17116/patol20238502121</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin. 2021;71(1):47–77. doi: 10.3322/caac.21636</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Arnaud M, Loiselle M, Vaganay C, et al. Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms. J Am Soc Nephrol. 2022;33(6):1154–1171. doi: 10.1681/ASN.2021070997</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hu X, Wang G, Cheng H. Specific antigens in malignancy-associated membranous nephropathy. Front Med. 2024;11:1368457. doi: 10.3389/fmed.2024.1368457</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Baker LW, Jimenez-Lopez J, Geiger XJ, Aslam N. Malignancy-Associated Membranous Nephropathy with Positive Anti-PLA2R Autoantibodies: Coincidence or Connection. Case Rep Nephrol Dial. 2021;11(3):334–339. doi: 10.1159/000520399</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18(7):466–478. doi: 10.1038/s41581-022-00564-1</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Xu Q, Li J, Yang Y, et al. Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study. Ren Fail. 2024;46(1):2355353. doi: 10.1080/0886022X.2024.2355353</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Plaisier E, Ronco P. Screening for Cancer in Patients with Glomerular Diseases. Clin J Am Soc Nephrol. 2020;15(6):886–888. doi: 10.2215/CJN.09000819</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98(5):1253–1264. doi: 10.1016/j.kint.2020.05.030</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Efe O, So PNH, Anandh U, et al. An Updated Review of Membranous Nephropathy. Indian J Nephrol. 2024;34(2):105–118. doi: 10.25259/ijn_317_23</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Fu N, Yuan S, Yang G, et al. Concurrent glomerular PCDH7 deposits in PLA2R-associated membranous nephropathy. CEN Case Rep. 2024;13(4):297–301. doi: 10.1007/s13730-023-00842-2</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Sethi S, Madden B, Debiec H, et al. Protocadherin 7-Associated Membranous Nephropathy. J Am Soc Nephrol. 2021;32(5):1249–1261. doi: 10.1681/ASN.2020081165</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sethi S, Madden B, Casal Moura M, et al. Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. J Am Soc Nephrol. 2022;33(5):1033–1044. doi: 10.1681/ASN.2021111488</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. 2021;100(1):171–181. doi: 10.1016/j.kint.2020.09.016</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Moroni G, Ponticelli C. Secondary Membranous Nephropathy. A Narrative Review. Front Med. 2020;7:611317. doi: 10.3389/fmed.2020.611317</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Dantas M, Silva LBB, Pontes BTM, et al. Membranous nephropathy. J Bras Nefrol. 2023;45(2):229–243. doi: 10.1590/2175-8239-JBN-2023-0046en</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ronco P, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. Annu Rev Pathol. 2020;15:287–313. doi: 10.1146/annurev-pathol-020117-043811</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gu Y, Xu H, Tang D. Mechanisms of Primary Membranous Nephropathy. Biomolecules. 2021;11(4):513. doi: 10.3390/biom11040513</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>McDonnell T, Wu HHL, Sinha S, Chinnadurai R. The Role of PLA2R in Primary Membranous Nephropathy: Do We Still Need a Kidney Biopsy? Genes. 2023;14(7):1343. doi: 10.3390/genes14071343</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Ragy O, Rautemaa V, Smith A, et al. Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy? PLoS One. 2023;18(2):e0281726. doi: 10.1371/journal.pone.0281726</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Kaya B, Paydas S, Balal M, et al. Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings. Int J Clin Pract. 2021;75(4):e13855. doi: 10.1111/ijcp.13855</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Kukuy OL, Cohen R, Gilburd B, et al. The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous Nephropathy. Int J Mol Sci. 2023;24(10):9051. doi: 10.3390/ijms24109051</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Mathew D, Gupta S, Ashman N. A case report of breast cancer and membranous nephropathy with positive anti phospholipase A2 receptor antibodies. BMC Nephrol. 2021;22(1):324. doi: 10.1186/s12882-021-02511-x</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Bobart SA, Han H, Tehranian S, et al. Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study. Clin J Am Soc Nephrol. 2021;16(12):1833–1839. doi: 10.2215/CJN.05480421</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Zhang C, Zhang M, Chen D, et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. J Clin Pathol. 2019;72(10):705–711. doi: 10.1136/jclinpath-2019-205852</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Juarez A, Galindo L, Ragunathan A, Gondal M. Thrombospondin Type 1 Domain-Containing 7A (THSD7A)-Associated Membranous Nephropathy Leading to Metastatic Neuroendocrine Carcinoma. Cureus. 2023;15(2):e35277. doi: 10.7759/cureus.35277</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Tesar V, Hruskova Z. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. Front Immunol. 2021;12:593288. doi: 10.3389/fimmu.2021.593288</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306–313. doi: 10.1080/0886022X.2018.1456457</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Shen K, Chen B, Yang L, Gao W. Integrated analysis of single-cell and bulk RNA-sequencing data reveals the prognostic value and molecular function of THSD7A in gastric cancer. Aging. 2023;15(21):11940–11969. doi: 10.18632/aging.205158</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163–174. doi: 10.1016/j.kint.2019.09.014</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2021;99(4):967–976. doi: 10.1016/j.kint.2020.07.039</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Wang G, Sun L, Dong H, et al. Neural Epidermal Growth Factor-Like 1 Protein-Positive Membranous Nephropathy in Chinese Patients. Clin J Am Soc Nephrol. 2021;16(5):727–735. doi: 10.2215/CJN.11860720</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Wang G, Hu X, Ye N, et al. Analysis of Clinicopathological Characteristics of Malignancy Patients with Membranous Nephropathy and Literature Review. Cancer Manag Res. 2024;16:677–689. doi: 10.2147/CMAR.S465211</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Qin HZ, Zhang MC, Le WB, et al. Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy. J Am Soc Nephrol. 2016;27(10):3195–3203. doi: 10.1681/ASN.2015080953</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Yasuda I, Tokuyama H, Hashiguchi A, et al. Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma. CEN Case Rep. 2021;10(2):281–286. doi: 10.1007/s13730-020-00556-9</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Matsumoto A, Matsui I, Mano K, et al. Recurrent membranous nephropathy with a possible alteration in the etiology: a case report. BMC Nephrol. 2021;22(1):253. doi: 10.1186/s12882-021-02457-0</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Chen M, Zhang L, Zhong W, et al. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. Front Immunol. 2021;12:619147. doi: 10.3389/fimmu.2021.619147</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19(3):574–9. doi: 10.1093/ndt/gfg616</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Sugihara A, Ureshino H, Yamasaki M, et al. Type II Cryoglobulinemic Membranoproliferative Glomerulonephritis Caused by Mucosa-associated Lymphoid Tissue Lymphoma. Intern Med. 2023;62(13):1983–1988. doi: 10.2169/internalmedicine.0756-22</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Pattanashetti N, Kapatia G, Nada R, et al. Association of Membranoproliferative Glomerulonephritis with Papillary Carcinoma Thyroid. Indian J Nephrol. 2019;29(5):368–369. doi: 10.4103/ijn.IJN_215_18</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Kakeshita K, Yamazaki H, Imamura T, et al. Cryofibrinogen-associated glomerulonephritis accompanied by advanced gastric cancer. CEN Case Rep. 2021;10(4):527–536. doi: 10.1007/s13730-021-00602-0</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Severova G, Karanfilovski V, Naunovska L, et al. Association Between Membranoproliferative Glomerulonephritis and Colorectal Cancer – A Case Report. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2024;45(2):31–36. doi: 10.2478/prilozi-2024-0013</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Taira S, Kawagoe M, Anzai H, et al. Immunoglobulin A-dominant membranoproliferative glomerulonephritis-like pattern of injury as a possible paraneoplastic nephropathy in a breast cancer patient. CEN Case Rep. 2024. doi: 10.1007/s13730-024-00936-5</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Dabrowski D, Ozluk E, Barbeito S, Wei EX. Focal Segmental Glomerulosclerosis Preceding Type 2 Papillary Renal Cell Carcinoma. Case Rep Pathol. 2020;2020:8811905. doi: 10.1155/2020/8811905</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Zhou J, Yang Z, Yang CS, Lin H. Paraneoplastic focal segmental glomerulosclerosis associated with gastrointestinal stromal tumor with cutaneous metastasis: A case report. World J Clin Cases. 2021;9(27):8120–8126. doi: 10.12998/wjcc.v9.i27.8120</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Gupta P, Gupta RK. Pathology of Glomerular Diseases. Atlas of Clinical Case Studies. Springer; 2022. doi: 10.1007/978-981-19-1430-0</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Masuda S, Koizumi K, Moriya H, et al. Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy. Intern Med. 2021;60(2):251–257. doi: 10.2169/internalmedicine.5499-20</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Cai X, Wu Y, Wan Q, Zhang X. Minimal change disease associated with thyroid cancer: a case report. Front Med. 2023;10:1132259. doi: 10.3389/fmed.2023.1132259</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Nakano Y, Yoshida M, Muraki N, et al. Prostate Cancer Associated with Minimal Change Disease: A Case Report. Glomerular Dis. 2022;2(3):145–150. doi: 10.1159/000525040</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Mei Z, Li F, Chen R, et al. Causal associations between thyroid cancer and IgA nephropathy: a Mendelian randomization study. BMC Genomics. 2023;24(1):525. doi: 10.1186/s12864-023-09633-6</mixed-citation></ref></ref-list></back></article>
